Skip To Content

Study ID: Merck MK-3475-426 Keynote 426

Title:

A Phase III randomized, open-label, clinical trial to study the efficacy and safety of pembrolizumab (MK3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced/metastatic renal cell carcinoma (mRCC)

Location:
Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD
Disease:
Other
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.